Trials / Unknown
UnknownNCT04368962
DSA Risk Factors in MMF-based Immunosuppressed Post-transplanted Patients
DSA Risk Factors in Chinese Kidney Transplant Patients Using MPA-based Immunosuppression Protocol: A Multi-center Clinical Study
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 300 (estimated)
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Kidney transplantation is the best therapy method for patients with uremia. The main factors affecting the long-term survival of the graft were chronic antibody-mediated rejection and the death of the patients. Newborn donor special antibody (DSA) is a major risk factor for chronic antibody-mediated rejection (AMR) and poor transplantation outcomes. Detection of mycophenolate mofetil (MMF) trough concentration can help estimate its exposure. Deficient exposure of MMF can lead to AMR after transplantation surgery. The aim of this study is to estimate the risk factors of one-year DSA after transplantation.
Conditions
Timeline
- Start date
- 2021-01-22
- Primary completion
- 2022-12-22
- Completion
- 2023-12-01
- First posted
- 2020-04-30
- Last updated
- 2022-05-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04368962. Inclusion in this directory is not an endorsement.